Marc Lombès
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marc Lombès has a total of 349 co-authors. Here are the top co-authors by number of shared publications:
- Say Viengchareun
Physiologie et Physiopathologie Endocriniennes, Université Paris-Saclay, Inserm, 94276 Le Kremlin-Bicêtre, France
31 shared publications Geri Meduri
INSERM U693 and Univ Paris-Sud 11, Faculté de Médecine Paris-Sud, UMR-S693, Le Kremlin Bicêtre F-94276, France
11 shared publications- Jérôme Fagart
Inserm U1185, Le-Kremlin-Bicêtre, France
9 shared publications - Philippe Chanson
Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l’Hypophyse (HYPO) , Le Kremlin-Bicêtre 94275
9 shared publications - Séverine Trabado
Assistance publique–Hôpitaux de Paris, hôpital Bicêtre, service de génétique moléculaire, pharmacogénétique et hormonologie, Le Kremlin-Bicêtre, France
9 shared publications Jérôme Bouligand
Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche_S U1185, Faculty of Medicine at Université Paris-Sud, University Paris-Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France
8 shared publications
Latest Publications
- 1 October 2022
- Published by Wolters Kluwer Health in Hypertension
- Vol. 79 (10) , 2262-2273
Mineralocorticoid Receptor Antagonism by Finerenone Attenuates Established Pulmonary Hypertension in Rats
Background: We studied the ability of the nonsteroidal MR (mineralocorticoid receptor) antagonist finerenone to attenuate vascular remodeling and pulmonary hypertension using two complementary preclinical models (the monocrotaline and sugen/hypoxia rat models) of severe pulmonary hypertension. Methods: We first examined the distribution pattern of MR in the lungs of patients with pulmonary arterial hypertension (PAH) and in monocrotaline and sugen/hypoxia rat lungs. Subsequent studies were performed to explore the effect of MR inhibition on proliferation of pulmonary artery smooth muscle cells derived from patients with idiopathic PAH. To validate the functional importance of MR activation in the pulmonary vascular remodeling characteristic of pulmonary hypertension, mice overexpressing human MR (hMR+) were studied, and curative treatments with finerenone (1 mg/kg per day by gavage), started 2 weeks after monocrotaline injection or 5 weeks after Sugen injection were realized. Results: We demonstrated that MR is overexpressed in experimental and human PAH and that its inhibition following small interfering RNA-mediated MR silencing or finerenone treatment attenuates proliferation of pulmonary artery smooth muscle cells derived from patients with idiopathic PAH. In addition, we obtained evidence that hMR+ mice display increased right ventricular systolic pressure, right ventricular hypertrophy, and remodeling of pulmonary arterioles. Consistent with these observations, curative treatments with finerenone partially reversed established pulmonary hypertension, reducing total pulmonary vascular resistance and vascular remodeling. Finally, we found that continued finerenone treatment decreases inflammatory cell infiltration and vascular cell proliferation in monocrotaline and sugen/hypoxia rat lungs. Conclusions: Finerenone treatment appears to be a potential therapy for PAH worthy of investigation and evaluation for clinical use in conjunction with current PAH treatments.
- 1 October 2022
- Published by Wolters Kluwer Health in Hypertension
- Vol. 79 (10) , 2262-2273
Mineralocorticoid Receptor Antagonism by Finerenone Attenuates Established Pulmonary Hypertension in Rats
Background: We studied the ability of the nonsteroidal MR (mineralocorticoid receptor) antagonist finerenone to attenuate vascular remodeling and pulmonary hypertension using two complementary preclinical models (the monocrotaline and sugen/hypoxia rat models) of severe pulmonary hypertension. Methods: We first examined the distribution pattern of MR in the lungs of patients with pulmonary arterial hypertension (PAH) and in monocrotaline and sugen/hypoxia rat lungs. Subsequent studies were performed to explore the effect of MR inhibition on proliferation of pulmonary artery smooth muscle cells derived from patients with idiopathic PAH. To validate the functional importance of MR activation in the pulmonary vascular remodeling characteristic of pulmonary hypertension, mice overexpressing human MR (hMR+) were studied, and curative treatments with finerenone (1 mg/kg per day by gavage), started 2 weeks after monocrotaline injection or 5 weeks after Sugen injection were realized. Results: We demonstrated that MR is overexpressed in experimental and human PAH and that its inhibition following small interfering RNA-mediated MR silencing or finerenone treatment attenuates proliferation of pulmonary artery smooth muscle cells derived from patients with idiopathic PAH. In addition, we obtained evidence that hMR+ mice display increased right ventricular systolic pressure, right ventricular hypertrophy, and remodeling of pulmonary arterioles. Consistent with these observations, curative treatments with finerenone partially reversed established pulmonary hypertension, reducing total pulmonary vascular resistance and vascular remodeling. Finally, we found that continued finerenone treatment decreases inflammatory cell infiltration and vascular cell proliferation in monocrotaline and sugen/hypoxia rat lungs. Conclusions: Finerenone treatment appears to be a potential therapy for PAH worthy of investigation and evaluation for clinical use in conjunction with current PAH treatments.
- Open Access
- 8 January 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (2) , e21314
Antagonistic effects of finerenone and spironolactone on the aldosterone‐regulated transcriptome of human kidney cells
Aldosterone, the main mineralocorticoid hormone in humans, plays a pivotal role in the control of water and salt reabsorption via activation of the mineralocorticoid receptor (MR). Alterations in MR signaling pathway lead to renal dysfunction, including chronic kidney disease and renal fibrosis, that can be prevented or treated with mineralocorticoid receptor antagonists (MRAs). Here, we used RNA‐Sequencing to analyze effects of two MRAs, spironolactone and finerenone, on the aldosterone‐induced transcriptome of a human renal cell line stably expressing the MR. Bioinformatics analysis of the data set reveals the identity of hundreds of genes induced or repressed by aldosterone. Their regulation is modulated in a time‐dependent manner and, for the induced genes, depends on the aldosterone‐driven direct binding of the MR onto its genomic targets that we have previously characterized. Although both MRAs block aldosterone‐induced as well as aldosterone‐repressed genes qualitatively similarly, finerenone has a quantitatively more efficient antagonism on some aldosterone‐induced genes. Our data provide the first complete transcriptome for aldosterone on a human renal cell line and identifies pro‐inflammatory markers ( IL6, IL11, CCL7, and CXCL8 ) as aldosterone‐repressed genes.
- 8 January 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (2) , e21314
Open AccessAntagonistic effects of finerenone and spironolactone on the aldosterone‐regulated transcriptome of human kidney cells
Aldosterone, the main mineralocorticoid hormone in humans, plays a pivotal role in the control of water and salt reabsorption via activation of the mineralocorticoid receptor (MR). Alterations in MR signaling pathway lead to renal dysfunction, including chronic kidney disease and renal fibrosis, that can be prevented or treated with mineralocorticoid receptor antagonists (MRAs). Here, we used RNA‐Sequencing to analyze effects of two MRAs, spironolactone and finerenone, on the aldosterone‐induced transcriptome of a human renal cell line stably expressing the MR. Bioinformatics analysis of the data set reveals the identity of hundreds of genes induced or repressed by aldosterone. Their regulation is modulated in a time‐dependent manner and, for the induced genes, depends on the aldosterone‐driven direct binding of the MR onto its genomic targets that we have previously characterized. Although both MRAs block aldosterone‐induced as well as aldosterone‐repressed genes qualitatively similarly, finerenone has a quantitatively more efficient antagonism on some aldosterone‐induced genes. Our data provide the first complete transcriptome for aldosterone on a human renal cell line and identifies pro‐inflammatory markers ( IL6, IL11, CCL7, and CXCL8 ) as aldosterone‐repressed genes.
- Open Access
- 1 December 2020
- Published by Elsevier in Molecular Metabolism
- Vol. 42, 101083
Changes in circulating miRNA19a-3p precede insulin resistance programmed by intra-uterine growth retardation in mice
- 1 December 2020
- Published by Elsevier in Molecular Metabolism
- Vol. 42, 101083
Open AccessChanges in circulating miRNA19a-3p precede insulin resistance programmed by intra-uterine growth retardation in mice
- 1 February 2020
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 182 (2) , R15-R27
GENETICS IN ENDOCRINOLOGY: Glucocorticoid resistance syndrome
Glucocorticoids (GC) such as cortisol regulate multiple physiological functions, notably those involved in development, metabolism, inflammatory processes and stress, and exert their effects upon binding to the glucocorticoid receptor (GR, encoded by NR3C1 gene in humans). GC signaling follows several consecutive steps leading to target gene transactivation, including ligand binding, nuclear translocation of ligand-activated GR complexes, DNA binding, and recruitment of functional transcriptional machinery. Generalized glucocorticoid resistance syndrome, due to GR loss-of-function mutations, may be related to the impairment of one of the GC signaling steps. To date, 31 NR3C1 loss-of-function mutations have been reported in patients presenting with various clinical signs such as hypertension, adrenal hyperplasia, hirsutism or metabolic disorders associated with biological hypercortisolism but without Cushing syndrome signs and no negative regulatory feedback loop on the hypothalamic-pituitary-adrenal axis. Functional characterization of GR loss-of-function mutations often demonstrates GR haploinsufficiency and a decrease of GR target gene induction in relevant cell types. The main signs at presentation are very variable from resistant hypertension, bilateral adrenal hyperplasia likely related to increased ACTH levels but not exclusively, hirsutism to isolated renin-angiotensin-aldosterone system abnormalities in a context of 11βHSD2 deficiency. Some mutated GR patients are obese or overweight together with a healthier metabolic profile that remains to be further explored in future studies. Deciphering the molecular mechanisms altered by GR mutations should enhance our knowledge on GR signaling and ultimately facilitate management of GC-resistant patients. This review also focuses on the criteria facilitating identification of novel NR3C1 mutations in selected patients.
- 1 February 2020
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 182 (2) , R15-R27
GENETICS IN ENDOCRINOLOGY: Glucocorticoid resistance syndrome
Glucocorticoids (GC) such as cortisol regulate multiple physiological functions, notably those involved in development, metabolism, inflammatory processes and stress, and exert their effects upon binding to the glucocorticoid receptor (GR, encoded by NR3C1 gene in humans). GC signaling follows several consecutive steps leading to target gene transactivation, including ligand binding, nuclear translocation of ligand-activated GR complexes, DNA binding, and recruitment of functional transcriptional machinery. Generalized glucocorticoid resistance syndrome, due to GR loss-of-function mutations, may be related to the impairment of one of the GC signaling steps. To date, 31 NR3C1 loss-of-function mutations have been reported in patients presenting with various clinical signs such as hypertension, adrenal hyperplasia, hirsutism or metabolic disorders associated with biological hypercortisolism but without Cushing syndrome signs and no negative regulatory feedback loop on the hypothalamic-pituitary-adrenal axis. Functional characterization of GR loss-of-function mutations often demonstrates GR haploinsufficiency and a decrease of GR target gene induction in relevant cell types. The main signs at presentation are very variable from resistant hypertension, bilateral adrenal hyperplasia likely related to increased ACTH levels but not exclusively, hirsutism to isolated renin-angiotensin-aldosterone system abnormalities in a context of 11βHSD2 deficiency. Some mutated GR patients are obese or overweight together with a healthier metabolic profile that remains to be further explored in future studies. Deciphering the molecular mechanisms altered by GR mutations should enhance our knowledge on GR signaling and ultimately facilitate management of GC-resistant patients. This review also focuses on the criteria facilitating identification of novel NR3C1 mutations in selected patients.
- Open Access
- 21 June 2019
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 104 (11) , 5205-5216
Impaired 11β-Hydroxysteroid Dehydrogenase Type 2 in Glucocorticoid-Resistant Patients
Context Six patients carrying heterozygous loss-of-function mutations of glucocorticoid (GC) receptor (GR) presented with hypercortisolism, associated with low kalemia, low plasma renin, and aldosterone levels, with or without hypertension, suggesting a pseudohypermineralocorticism whose mechanisms remain unclear. We hypothesize that an impaired activity of the 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2; encoded by the HSD11B2 gene), catalyzing cortisol (F) inactivation, may account for an inappropriate activation of a renal mineralocorticoid signaling pathway in these GC-resistant patients. Objective We aim at studying the GR-mediated regulation of HSD11B2. Design The HSD11B2 promoter was subcloned and luciferase reporter assays evaluated GR-dependent HSD11B2 regulation, and 11β-HSD2 expression/activity was studied in human breast cancer MCF7 cells, endogenously expressing this enzyme. Results Transfection assays revealed that GR transactivated the long (2.1-kbp) HSD11B2 promoter construct, whereas a defective 501H GR mutant was unable to stimulate luciferase activity. GR-mediated transactivation of the HSD11B2 gene was inhibited by the GR antagonist RU486. A threefold increase in HSD11B2 mRNA levels was observed after dexamethasone (DXM) treatment of MCF7 cells, inhibited by RU486 or by actinomycin, supporting a GR-dependent transcription. Chromatin immunoprecipitation further demonstrated a DXM-dependent GR recruitment onto the HSD11B2 promoter. 11β-HSD2 activity, evaluated by the cortisone/F ratio, quantified by liquid chromatography/tandem mass spectrometry, was 10-fold higher in the supernatant of DXM-treated cells than controls, consistent with a GR-dependent stimulation of 11β-HSD2 catalytic activity. Conclusion Collectively, we demonstrate that 11β-HSD2 expression and activity are transcriptionally regulated by GR. In the context of GR haploinsufficiency, these findings provide evidence that defective GR signaling may account for apparent mineralocorticoid excess in GC-resistant patients.
- 21 June 2019
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 104 (11) , 5205-5216
Open AccessImpaired 11β-Hydroxysteroid Dehydrogenase Type 2 in Glucocorticoid-Resistant Patients
Context Six patients carrying heterozygous loss-of-function mutations of glucocorticoid (GC) receptor (GR) presented with hypercortisolism, associated with low kalemia, low plasma renin, and aldosterone levels, with or without hypertension, suggesting a pseudohypermineralocorticism whose mechanisms remain unclear. We hypothesize that an impaired activity of the 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2; encoded by the HSD11B2 gene), catalyzing cortisol (F) inactivation, may account for an inappropriate activation of a renal mineralocorticoid signaling pathway in these GC-resistant patients. Objective We aim at studying the GR-mediated regulation of HSD11B2. Design The HSD11B2 promoter was subcloned and luciferase reporter assays evaluated GR-dependent HSD11B2 regulation, and 11β-HSD2 expression/activity was studied in human breast cancer MCF7 cells, endogenously expressing this enzyme. Results Transfection assays revealed that GR transactivated the long (2.1-kbp) HSD11B2 promoter construct, whereas a defective 501H GR mutant was unable to stimulate luciferase activity. GR-mediated transactivation of the HSD11B2 gene was inhibited by the GR antagonist RU486. A threefold increase in HSD11B2 mRNA levels was observed after dexamethasone (DXM) treatment of MCF7 cells, inhibited by RU486 or by actinomycin, supporting a GR-dependent transcription. Chromatin immunoprecipitation further demonstrated a DXM-dependent GR recruitment onto the HSD11B2 promoter. 11β-HSD2 activity, evaluated by the cortisone/F ratio, quantified by liquid chromatography/tandem mass spectrometry, was 10-fold higher in the supernatant of DXM-treated cells than controls, consistent with a GR-dependent stimulation of 11β-HSD2 catalytic activity. Conclusion Collectively, we demonstrate that 11β-HSD2 expression and activity are transcriptionally regulated by GR. In the context of GR haploinsufficiency, these findings provide evidence that defective GR signaling may account for apparent mineralocorticoid excess in GC-resistant patients.
- 3 April 2019
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 54 (6) , 2149-2156
Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management
Mitotane (also termed o,p '-DDD) is the most effective therapy for advanced adrenocortical carcinoma (ACC). Mitotane-induced dyslipidemia is treated with statins. Mitotane and statins are known to exert anti-proliferative effects in vitro; however, the effects of statins have never been directly evaluated in patients with ACC and ACC cells, at least to the best of our knowledge. Thus, in this study, we aimed to examine the effects of the rosuvastatin on ACC cells. It has been shown that the combined use of mitotane and statins significantly increases the tumor control rate in patients with ACC; however, it would be of interest to elucidate the molecular mechanisms involved in this potentiation. In this study, we examined the effects of mitotane, rosuvastatin and their combination in NCI-H295R human ACC cells using proliferation assays, gene expression analyses and free intracellular cholesterol measurements. The results revealed that mitotane dose-dependently reduced cell viability, induced apoptosis and increased intracellular free cholesterol levels, considered as one of the key features of mitotane action, while rosuvastatin alone reduced cell viability and increased apoptosis at high concentrations. We also demonstrated that rosuvastatin potentiated the effects of mitotane by reducing cell viability, inducing apoptosis, increasing intracellular free cholesterol levels, and by decreasing the expression of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and ATP binding cassette subfamily a member 1 (ABCA1), genes involved in cholesterol metabolism, and inhibiting steroidogenesis. Collectively, potentiating the effects of mitotane with the use of rosuvastatin may provide novel therapeutic strategies for ACC, given that the combination of these drugs, pending clinical validation, may lead to the better management of ACC.
- 3 April 2019
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 54 (6) , 2149-2156
Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management
Mitotane (also termed o,p '-DDD) is the most effective therapy for advanced adrenocortical carcinoma (ACC). Mitotane-induced dyslipidemia is treated with statins. Mitotane and statins are known to exert anti-proliferative effects in vitro; however, the effects of statins have never been directly evaluated in patients with ACC and ACC cells, at least to the best of our knowledge. Thus, in this study, we aimed to examine the effects of the rosuvastatin on ACC cells. It has been shown that the combined use of mitotane and statins significantly increases the tumor control rate in patients with ACC; however, it would be of interest to elucidate the molecular mechanisms involved in this potentiation. In this study, we examined the effects of mitotane, rosuvastatin and their combination in NCI-H295R human ACC cells using proliferation assays, gene expression analyses and free intracellular cholesterol measurements. The results revealed that mitotane dose-dependently reduced cell viability, induced apoptosis and increased intracellular free cholesterol levels, considered as one of the key features of mitotane action, while rosuvastatin alone reduced cell viability and increased apoptosis at high concentrations. We also demonstrated that rosuvastatin potentiated the effects of mitotane by reducing cell viability, inducing apoptosis, increasing intracellular free cholesterol levels, and by decreasing the expression of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and ATP binding cassette subfamily a member 1 (ABCA1), genes involved in cholesterol metabolism, and inhibiting steroidogenesis. Collectively, potentiating the effects of mitotane with the use of rosuvastatin may provide novel therapeutic strategies for ACC, given that the combination of these drugs, pending clinical validation, may lead to the better management of ACC.
- Open Access
- 6 March 2019
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 3 (5) , 865-881
Functional Characterization of Glucocorticoid Receptor Variants Is Required to Avoid Misinterpretation of NGS Data
Recent advances in genetic analysis technologies such as Next Generation Sequencing (NGS), has considerably increased the incidental discovery of genetic abnormalities. Six heterozygous missense mutations of the human glucocorticoid receptor, hGR (encoded by the NR3C1 gene), have been identified in the context of genetic screening of endocrine pathologies. GR, a nuclear receptor, hormone-induced transcription factor, is involved in many physiological processes. Nevertheless, the pathogenic significance of incidentally discovered mutations remains obscure. The aim of this work was to characterize these new variants evaluating their functional impact on GR signaling. Six original GR variants, located in exon 2, lead to amino acid substitutions of the N-terminal domain of GR (F65V, M86V, A229T, A304E, N374S, R386Q), mainly excluding the activation function τ1 domain, potential site of functional interaction with transcriptional coregulators. Transient co-transfection in HEK293T cells of mutated GR expressing vectors and a luciferase reporter establishes dose-response curves for dexamethasone. This excluded any major transactivation abnormality of the mutated GRs (EC50 ≈ 0.2nM), identical maximal transactivation capacity than that of the wild-type (WT GR), without modification of the potentiation of transcriptional coactivator SRC2, except N374S. Moreover, protein expression of mutated GRs and their cytonuclear translocation studied by immunocytochemistry were almost unchanged as compared to WT GR. These results underline the silent nature of these missense GR variants and call for a cautious interpretation of the discovery of genetic incidentalomas by NGS in the absence of detailed characterization to appropriately assess their functional impact on a particular signaling pathway.
- 6 March 2019
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 3 (5) , 865-881
Open AccessFunctional Characterization of Glucocorticoid Receptor Variants Is Required to Avoid Misinterpretation of NGS Data
Recent advances in genetic analysis technologies such as Next Generation Sequencing (NGS), has considerably increased the incidental discovery of genetic abnormalities. Six heterozygous missense mutations of the human glucocorticoid receptor, hGR (encoded by the NR3C1 gene), have been identified in the context of genetic screening of endocrine pathologies. GR, a nuclear receptor, hormone-induced transcription factor, is involved in many physiological processes. Nevertheless, the pathogenic significance of incidentally discovered mutations remains obscure. The aim of this work was to characterize these new variants evaluating their functional impact on GR signaling. Six original GR variants, located in exon 2, lead to amino acid substitutions of the N-terminal domain of GR (F65V, M86V, A229T, A304E, N374S, R386Q), mainly excluding the activation function τ1 domain, potential site of functional interaction with transcriptional coregulators. Transient co-transfection in HEK293T cells of mutated GR expressing vectors and a luciferase reporter establishes dose-response curves for dexamethasone. This excluded any major transactivation abnormality of the mutated GRs (EC50 ≈ 0.2nM), identical maximal transactivation capacity than that of the wild-type (WT GR), without modification of the potentiation of transcriptional coactivator SRC2, except N374S. Moreover, protein expression of mutated GRs and their cytonuclear translocation studied by immunocytochemistry were almost unchanged as compared to WT GR. These results underline the silent nature of these missense GR variants and call for a cautious interpretation of the discovery of genetic incidentalomas by NGS in the absence of detailed characterization to appropriately assess their functional impact on a particular signaling pathway.
- 1 February 2019
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 80 (1) , 1-9
UCP1 transrepression in Brown Fat in vivo and mineralocorticoid receptor anti-thermogenic effects
- 1 February 2019
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 80 (1) , 1-9
UCP1 transrepression in Brown Fat in vivo and mineralocorticoid receptor anti-thermogenic effects
- 1 January 2019
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 99, 47-56
Glucocorticoids stimulate hypothalamic dynorphin expression accounting for stress-induced impairment of GnRH secretion during preovulatory period
- 1 January 2019
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 99, 47-56
Glucocorticoids stimulate hypothalamic dynorphin expression accounting for stress-induced impairment of GnRH secretion during preovulatory period
- 24 August 2018
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 79 (4) , 213
Anomalies chromosomiques et architecture sous-clonale des adénomes somatotropes
- 24 August 2018
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 79 (4) , 213
Anomalies chromosomiques et architecture sous-clonale des adénomes somatotropes